文献速递妇科

绝经类型、绝经年龄与心血管疾病发病风险变异:10项国际研究个体数据汇总分析

Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies.
PubMed 文献 · Hum Reprod · 2020-01-01

该研究汇总10项观察性研究203767名绝经后女性个体数据,分析绝经类型和年龄与心血管疾病(CVD)风险的关系。与自然绝经相比,手术绝经与CVD风险升高相关(HR 1.22,95%CI 1.16-1.28);绝经年龄越小风险越高,且绝经类型与年龄存在交互作用(P<0.001)。早期手术绝经女性使用激素替代治疗(HRT)者冠心病风险低于未使用者。

要点

  • 手术绝经与自然绝经相比,CVD风险升高(HR 1.22,95%CI 1.16-1.28)。
  • 绝经年龄越小,CVD风险越高,且绝经类型与年龄存在交互作用(P<0.001)。
  • 早期手术绝经(<50岁)女性使用HRT者冠心病风险低于未使用者。

核心结论

  • 与同年龄自然绝经女性相比,早期手术绝经(如<45岁)与额外增加的CVD事件风险相关,HRT使用可降低早期手术绝经女性的CVD风险。
  • 作者认为,自然绝经或较早手术绝经的女性需要密切监测并参与预防性健康措施和CVD早期诊断。
  • 作者建议,基于CVD风险增加,良性病变子宫切除时行选择性双侧卵巢切除术(手术绝经)应被劝阻。

研究设计与样本

  • 汇总10项观察性研究的个体水平数据,纳入203767名绝经后女性,均来自InterLACE联盟。
  • 暴露为绝经类型(自然绝经和手术绝经)和绝经年龄(分为<35、35-39、40-44、45-49、50-54和≥55岁)。
  • 自然绝经定义为12个月无月经(无子宫切除和/或卵巢切除),手术绝经定义为双侧卵巢切除。
  • 结局为首次非致死性CVD事件(冠心病或卒中),通过医院病历或自我报告确定。
  • 采用Cox比例风险模型估计非致死性CVD事件的风险比(HR)和95%CI。

主要发现

  • 与自然绝经相比,手术绝经与CVD风险升高超过20%相关(HR 1.22,95%CI 1.16-1.28)。
  • 按绝经年龄分层后,自然绝经和手术绝经均呈现绝经年龄越低、CVD风险越高的分级关系。
  • 与50-54岁自然绝经相比,<35岁手术绝经(HR 2.55,95%CI 2.22-2.94)和35-39岁手术绝经(HR 1.91,95%CI 1.71-2.14)的CVD风险高于相应年龄自然绝经(HR 1.59,95%CI 1.23-2.05和HR 1.51,95%CI 1.33-1.72)。
  • 绝经类型与绝经年龄之间存在显著交互作用(P<0.001)。
  • 较早年龄(<50岁)手术绝经女性中使用HRT者,其冠心病发病风险低于未使用HRT者。

临床怎么用

  • 作者认为,自然绝经或较早手术绝经的女性需要密切监测并参与预防性健康措施和CVD早期诊断。
  • 作者建议,绝经时机应作为女性CVD风险评估的重要因素。
  • 作者建议,基于CVD风险增加,良性病变子宫切除时行选择性双侧卵巢切除术(手术绝经)应被劝阻。

局限性

  • 绝经类型和年龄为自我报告数据。
  • 无手术指征信息(如子宫内膜异位症和子宫肌瘤)。
  • 排除了致死性CVD事件,可能使结果产生偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: How does the risk of cardiovascular disease (CVD) vary with type and age of menopause? SUMMARY ANSWER: Earlier surgical menopause (e.g. <45 years) poses additional increased risk of incident CVD events, compared to women with natural menopause at the same age, and HRT use reduced the risk of CVD in women with early surgical menopause. WHAT IS KNOWN ALREADY: Earlier age at menopause has been linked to an increased risk of CVD mortality and all-cause mortality, but the extent that this risk of CVD varies by type of menopause and the role of postmenopausal HRT use in reducing this risk is unclear. STUDY DESIGN, SIZE, DURATION: Pooled individual-level data of 203 767 postmenopausal women from 10 observational studies that contribute to the International collaboration for a Life course Approach to reproductive health and Chronic disease Events (InterLACE) consortium were included in the analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Postmenopausal women who had reported menopause (type and age of menopause) and information on non-fatal CVD events were included. Type of menopause (natural menopause and surgical menopause) and age at menopause (categorised as <35, 35-39, 40-44, 45-49, 50-54 and ≥55 years) were exposures of interest. Natural menopause was defined as absence of menstruation over a period of 12 months (no hysterectomy and/or oophorectomy) and surgical menopause as removal of both ovaries. The study outcome was the first non-fatal CVD (defined as either incident coronary heart disease (CHD) or stroke) event ascertained from hospital medical records or self-reported. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% CI for non-fatal CVD events associated with natural menopause and surgical menopause. MAIN RESULTS AND THE ROLE OF CHANCE: Compared with natural menopause, surgical menopause was associated with over 20% higher risk of CVD (HR 1.22, 95% CI 1.16-1.28). After the stratified analysis by age at menopause, a graded relationship for incident CVD was observed with lower age at menopause in both types of natural and surgical menopause. There was also a significant interaction between type of menopause and age at menopause (P < 0.001). Compared with natural menopause at 50-54 years, women with surgical menopause before 35 (2.55, 2.22-2.94) and 35-39 years (1.91, 1.71-2.14) had higher risk of CVD than those with natural menopause (1.59, 1.23-2.05 and 1.51, 1.33-1.72, respectively). Women who experienced surgical menopause at earlier age (<50 years) and took HRT had lower risk of incident CHD than those who were not users of HRT. LIMITATIONS, REASONS FOR CAUTION: Self-reported data on type and age of menopause, no information on indication for the surgery (e.g. endometriosis and fibroids) and the exclusion of fatal CVD events may bias our results. WIDER IMPLICATIONS OF THE FINDINGS: In clinical practice, women who experienced natural menopause or had surgical menopause at an earlier age need close monitoring and engagement for preventive health measures and early diagnosis of CVD. Our findings also suggested that timing of menopause should be considered as an important factor in risk assessment of CVD for women. The findings on CVD lend some support to the position that elective bilateral oophorectomy (surgical menopause) at hysterectomy for benign diseases should be discouraged based on an increased risk of CVD. STUDY FUNDING/COMPETING INTEREST(S): InterLACE project is funded by the Australian National Health and Medical Research Council project grant (APP1027196). GDM is supported by Australian National Health and Medical Research Council Principal Research Fellowship (APP1121844). There are no competing interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Zhu D, Chung HF, Dobson AJ, et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod. 2020. PMID: 32563191. doi:10.1093/humrep/deaa124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。